Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bridge program keeps seizure drug available for eligible patients

NCT ID NCT02307578

NO_LONGER_AVAILABLE Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This program provides continued access to the seizure medication perampanel (Fycompa) for people who completed certain earlier studies and are still benefiting from the drug. It runs until the drug is commercially available in their country or no participants remain. Only those already in the program or specific prior studies are eligible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Perampanel (also known as Fycompa)
What this could lead to
If successful, this program ensures continued access to perampanel for people with certain seizure disorders until the drug is commercially available in their country.
What could go wrong
This is an access program, not a new trial, so it does not test new benefits or risks. Participants must have already shown a positive response to perampanel in prior studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy with generalized tonic-clonic seizures focal epilepsy Lennox-Gastaut syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LENNOX GASTAUT SYNDROME PRIMARY GENERALIZED TONIC-CLONIC OR PARTIAL ONSET SEIZURES

Contacts and locations

Locations

  • Artroscan

    Ostrava-Trebovice, Czechia

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház

    Miskolc, Hungary

  • Centre Neurologique William Lennox

    Ottignies, Belgium

  • Childrens University Hospital

    Riga, Latvia

  • Clinical Centre of Serbia

    Belgrade, Serbia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Dél-Pesti Centrumkórház Országos Hematológiai és Infektológiai Intézet

    Budapest, Hungary

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Padre Hurtado

    Santiago, Chile

  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Spain

  • Hospital Universitario Virgen del Rocio -

    Seville, Spain

  • Hôpital Universitaire des Enfants Reine Fabiola

    Brussels, Belgium

  • Instytut Psychiatrii Neurologii

    Warsaw, Poland

  • Klaipeda University Hospital

    Klaipėda, Lithuania

  • Magyarorszagi Reformatus Egyhaz (MRE) Bethesda Gyermekkorhaza

    Budapest, Hungary

  • NZOZ Centrum Neurologii Dzieciecej i Leczenia Padaczki

    Kielce, Poland

  • Nzoz Novo-Med

    Katowice, Poland

  • Országos Idegsebészeti Tudományos Intézet

    Budapest, Hungary

  • Oy Neurodiagnostika Ap

    Tallinn, Estonia

  • Pécsi Tudományegyetem

    Pécs, Hungary

  • Rajna és Fiai Kereskedelmi és Szolgáltató Kft.

    Budapest, Hungary

  • Riga 1st Hospital

    Riga, Latvia

  • Servus Salvus Egeszsegugyi Szolgaltato Kft.

    Budapest, Hungary

  • Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu

    Poznan, Poland

  • Tartu University Hospital

    Tartu, Estonia

  • Uniwersyteckie Centrum Kliniczne - PPDS

    Gdansk, Poland

  • Všeobecná fakultní nemocnice, Pragtis s.r.o

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.